OraSure faced a challenging 2025 with a 29% year-over-year revenue decline in Q4, primarily driven by lower HIV test sales and a drop in consumer genomics demand. Despite the revenue contraction and a significant operating loss, the company maintained a strong cash position of $199 million and is pivoting toward growth in 2026 through new FDA submissions for STI testing and molecular self-tests.

OraSure Technologies experienced a challenging third quarter in 2025, with total net revenues declining significantly by 32% to $27.1 million compared to the same period last year. This decline was primarily driven by decreases across its core business segments, including Diagnostics and Sample Management Solutions, as well as a near-complete cessation of COVID-19, Risk Assessment Testing, and Molecular Services revenues. Despite the downturn, the company remains optimistic about returning to growth in 2026 through diversification and new product launches, supported by a strong balance sheet.

OraSure Technologies experienced a substantial 43% decrease in total net revenues for Q2 2025, primarily driven by a near-complete decline in COVID-19 related revenues. Despite this, the core business saw a more modest 5% year-over-year decrease, with Diagnostics revenues showing a 3% increase. The company reported a significant GAAP net loss and operating loss, but highlighted progress in product portfolio expansion and strategic initiatives for future growth.

OraSure Technologies reported a significant decrease in total net revenues for Q1 2025, down 45% year-over-year, primarily driven by a 98% decline in COVID-19 revenues. Core business revenues saw a slight decrease of 2%. The company experienced increased GAAP and non-GAAP operating losses and net losses compared to the prior year.

OraSure Technologies reported a 51% decrease in total net revenues for Q4 2024, primarily due to a significant decline in COVID-19 revenues. Despite this, core revenues showed a 10% year-over-year growth, indicating a gradual recovery in key end markets and diversification efforts.

OraSure Technologies reported Q3 2024 revenue of $39.9 million, a 55% decrease compared to Q3 2023. Core revenues decreased by 1% year-over-year, while COVID-19 revenues declined significantly. The company is exiting its Risk Assessment testing business to focus on Diagnostics and Sample Management.

OraSure Technologies reported a 36% decrease in total net revenues to $54.3 million compared to Q2 2023. Core revenues decreased by 7% year-over-year. The company is focusing on strengthening its foundation, elevating its core business, and accelerating profitable growth through innovation and cost efficiency.

OraSure Technologies reported Q1 2024 revenue of $54.1 million. The company is undergoing restructuring initiatives expected to result in $15 million of annualized expense reductions and aims to achieve cash flow breakeven for its core business by the end of 2024. They also delivered initial orders for Syphilis Health Check™ as part of their distribution agreement with Diagnostics Direct.

OraSure Technologies reported a decrease in total net revenues for Q4 2023, with core revenue showing a slight increase and COVID-19 revenue declining. The company highlighted progress on its transformation journey, margin expansion, and focus on innovation and disciplined execution. They also entered the U.S. Syphilis testing market via a strategic distribution agreement with Diagnostics Direct.

OraSure Technologies reported a decrease in total net revenues but an increase in core revenue. The company saw improvements in gross margin and operating income, with GAAP EPS of $0.15 and non-GAAP EPS of $0.27. They also grew their cash balance to $224.9 million.

OraSure Technologies reported a 6% increase in net revenue to $85.4 million, driven by a 3% year-over-year growth in core revenue and a 10% increase in InteliSwab® test revenue. The company's cash balance grew to $185.9 million, and it is on track to achieve operating cash flow breakeven on its core business by the end of 2024.

OraSure Technologies reported a record revenue of $155.0 million in Q1 2023, a 129% increase from Q1 2022. The company saw growth in InteliSwab® test revenue and signed three new molecular partnerships. They also reduced their non-production workforce by 11% and improved their cash position to $112.4 million.

OraSure Technologies reported record revenue of $123.1 million for Q4 2022, a 94% increase year-over-year, driven by InteliSwab® sales. The company announced a restructuring plan expected to save $15 million in operating expenses and aims to achieve cash flow breakeven for its core business by the end of 2024. The cash balance increased to $111 million.

OraSure Technologies reported record revenue of $116.5 million for Q3 2022, a 116% increase year-over-year, driven by InteliSwab® revenue growth. The company achieved GAAP EPS of $0.07 and non-GAAP EPS of $0.13, and generated positive cash flow from operations ahead of prior guidance.

OraSure Technologies reported a record revenue of $80.2 million for Q2 2022, a 39% increase year-over-year, driven by InteliSwab® revenue growth which offset declines in the base diagnostic business and molecular solutions business. The company is undergoing a strategic transformation, including a new CFO appointment and changes to the Board of Directors. They expect to generate positive cash flow in Q4 2022.

OraSure Technologies reported a record revenue of $67.7 million for Q1 2022, a 16% increase year-over-year, with a 21% growth in non-COVID revenue. The company scaled InteliSwab® production, improved manufacturing efficiency, and saw strong demand for molecular kits.

OraSure Technologies reported fourth-quarter revenue of $63.6 million, a 1% increase year-over-year. The Diagnostics business unit saw a 58% increase in revenue, driven by InteliSwab®, while the Molecular Solutions business unit experienced a 27% decline due to lower COVID-19 molecular collection kit sales. The company reported a net loss of $10.4 million, or $0.14 per share.

OraSure Technologies reported a 12% increase in revenue for Q3 2021, driven by growth in the diagnostics business unit and genomics collection kit revenue. The company signed three major U.S. government contracts for InteliSwab™ COVID-19 Rapid Test procurement and manufacturing capacity build out.

OraSure Technologies reported a strong second quarter in 2021, with net revenues of $57.6 million, a 97% increase from Q2 2020. The company's core business rebounded to pre-pandemic levels, and it received three EUAs for its InteliSwab™ COVID-19 Rapid Tests. The Molecular Solutions business unit saw significant growth, driven by demand for genomic collection kits and microbiome services.

OraSure Technologies announced strong Q1 2021 results with net revenues of $58.6 million, an 85% increase year-over-year, driven by sales of sample collection devices for COVID-19 molecular testing. The company also submitted an EUA application to the FDA for its COVID-19 rapid antigen test.

OraSure Technologies, Inc. reported strong financial results for the fourth quarter of 2020, with revenue increasing by 41% compared to the same period in the previous year. The company's growth was primarily driven by increased demand for molecular collection devices, as well as strong performance in diagnostics. OraSure is optimistic about its future prospects and expects continued growth in the coming years.

OraSure Technologies announced strong top-line results in the third quarter, driven by the performance of its Molecular Solutions business unit, which marked its highest quarter ever, with $31.7 million in total revenue. The Company's ability to quickly respond to the need for increased COVID-19 testing resulted in $18.4 million in sales of sample collection devices for molecular testing in the third quarter.

OraSure Technologies reported a decrease in net revenues for the second quarter of 2020, but saw an increase in sales of oral fluid collection devices for COVID-19 molecular testing.

OraSure Technologies reported a 5% increase in net revenues for Q1 2020, reaching $31.6 million, with a net loss of $7.3 million or $0.12 per share. The company is also developing COVID-19 tests and sample collection methods.

OraSure Technologies reported Q4 2019 net revenues of $49.7 million, a 1% decrease from Q4 2018. Net income for the quarter was $2.4 million, or $0.04 per share.